FINWIRES · TerminalLIVE
FINWIRES

調査速報:ピンズ:第1四半期は予想を上回り、第2四半期の見通しも好調。海外事業の成長が際立つ。

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。PINSは第1四半期の売上高が10億800万ドル(前年同期比18%増)となり、市場予想の9億6,800万ドルを上回りました。調整後EBITDAも2億700万ドル(利益率20%)となり、市場予想の1億7,600万ドルを上回りました。同社は、人口統計や地域を問わずプラットフォームの魅力が持続的に高まったことで、10四半期連続で2桁のユーザー成長を達成し、グローバルMAUは6億3,100万人(前年同期比11%増)に達しました。国際市場は力強い勢いを見せ、欧州の売上高は前年同期比27%増の1億8,600万ドル、その他の地域は同59%増の7,200万ドルとなりました。ARPUも引き続き堅調に推移し、欧州のARPUは17%増、その他の地域は38%増となり、国際的な収益化戦略の有効性が証明されました。第2四半期の売上高見通しは11億3300万ドル~11億5300万ドル(14%~16%増)で、市場予想の11億2300万ドルを上回りました。同社は20億ドルの自社株買いプログラムを完了し、9億8500万ドルの転換社債を発行しました。これにより、現金残高は25億ドルから13億ドルに減少しましたが、戦略的なAIおよび製品開発への投資にもかかわらず、第1四半期には3億1200万ドルの堅調なフリーキャッシュフローを生み出しました。

Related Articles

Asia

Lottery Secures Agreement for 40-Year License Extension

Lottery (ASX:TLC) secured an agreement with the Victorian State Government for a 40-year extension of the public lottery license, according to a Tuesday filing with the Australian bourse.The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state, the filing said.Historically, the license has been offered on 10-year terms and was set to expire on June 30, 2028, per the filing.

$ASX:TLC
Asia

Gentrack Group Cuts Fiscal 2026 Revenue Guidance; Plans Buyback; Kiwi Shares Fall 22%

Gentrack Group (NZE:GTK, ASX:GTK) said it now expects fiscal year 2026 revenue of between NZ$229 million and NZ$238 million, lower than its previous guidance, according to a Tuesday filing with the Australian and New Zealand bourses.The company expects fiscal year 2026 recurring revenue to grow by over 10% to around NZ$174 million. It also expects fiscal first-half revenue of around NZ$110 million, of which roughly NZ$85 million would be recurring, per the filing.Gentrack said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of NZ$13.5 million to NZ$20 million, and fiscal first half EBITDA of about NZ$7.8 million, both excluding acquisition costs.The guidance comes as the company has decided "to prioritize growth and global leadership over short-term EBITDA" and continues to invest in international expansion and product development, it said.The company maintained its medium-term target of a more than 15% compound annual growth rate for revenue.Additionally, after the release of fiscal first-half results, Gentrack's board plans to launch an on-market share buyback for up to 5% of the company's issued shares, per the filing.The company's Kiwi shares fell 22% in recent Tuesday trade on the New Zealand bourse.

$ASX:GTK$NZE:GTK
Research

Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.

$VRTX